Two HIV-focused studies reported progress on both cure-directed biology and real-world prevention pipeline performance. In iScience, an iScience study showed that combining a selective CDK9 inhibitor with a PP2A-activating drug durably silenced HIV transcription in latency models, with persistence after withdrawal and reduced sensitivity to cocaine and morphine exposure. On implementation, an EHR-based approach under California’s new latent TB screening law drove a surge in blood testing—547 additional blood tests—but care cascade data showed that fewer than one in four eligible patients with positive results started treatment. While not HIV-specific, the same care-cascade bottleneck is a reminder that diagnostic automation often fails unless linkage to treatment is engineered. Finally, a separate trial imaging report indicated that first-line dolutegravir/lamivudine can reach lymph node reservoirs, coinciding with rapid declines in HIV-infected cells in lymph node tissue. Together, the cluster spans mechanistic suppression, compartment penetration, and the operational gap between diagnostics and treatment start. For industry readers, the through-line is measurable penetration and persistence—whether the goal is latency reversal resistance or linkage to downstream care—rather than relying on surrogate endpoints alone.